US ends PEPFAR funding to South Africa, exposing 8 million HIV patients to a $400M gap

Summary

The Trump administration confirmed on June 19 that the US will end US PEPFAR funding to South Africa, citing South Africa's failure to meet administration policy demands. The programme had provided roughly $400 million a year, covering about 17% of South Africa's total HIV response. South Africa carries the world's largest HIV burden, with more than 8 million people living with the virus. UNAIDS executive director Winnie Byanyima warned the cuts could cost lives. The decision follows a February 2025 executive order in which Donald Trump accused South Africa of permitting discrimination against white Afrikaners. South Africa's Department of Health said it had not received formal notification from Washington.

The split

US-wire and State Department framing frames the pullout as a consequence of South Africa's policy non-compliance, specifically on the Afrikaner discrimination issue. UNAIDS and European press lead with the public-health stakes: the world's largest HIV programme losing a fifth of its care funding. Cyril Ramaphosa's government has avoided direct confrontation, managing the announcement quietly while looking for alternative donors. The GNU coalition's internal politics complicate a unified response.

By the numbers

• $400M/year, US PEPFAR contribution to South Africa's HIV response
• 17%, share of South Africa's HIV funding from PEPFAR
• 8M+, people living with HIV in South Africa
• Feb 2025, when Trump's executive order first targeted South Africa aid flows

Why it matters

A $400 million funding gap cannot be quickly absorbed. South Africa's state health budget is already under pressure from fiscal consolidation. Without rapid bridging from the EU, the Global Fund, or domestic reallocation, treatment interruptions will drive antiretroviral resistance and preventable AIDS deaths. The spillover risk extends across southern Africa, where South Africa anchors regional HIV supply chains and training infrastructure. The decision also signals that the Trump administration is willing to use global health funding as diplomatic leverage.

What to watch

• Whether South Africa secures alternative donors (EU, Global Fund, PEPFAR emergency reserves) to bridge the gap
• Whether Pretoria makes concessions on Afrikaner policy to restore funding
• UNAIDS mortality modelling over the next 12-24 months
• How the funding cut affects South Africa's lenacapavir long-acting injection rollout, which began in June 2026